Catherine Robin-Jagerschmidt is a well-seasoned scientist with nearly 30 years of experience in drug discovery and development, specializing in in vivo pharmacology and translational research.

She earned her PhD in Developmental Molecular and Cellular Biology from the University of Paris-Diderot and began her career with postdoctoral research on steroid receptor structure-function relationships.

Throughout her career (Aventis, Proskelia, and Galapagos), she has led a multidisciplinary team working on nuclear receptors and selective androgen receptor modulators (SARMs), collaborating also with academic partners. She previously held leadership roles in in vivo pharmacology and in vivo optical imaging, advancing preclinical model development in inflammation and fibrosis (Galapagos).

Since 2023, she has been serving as Senior Project Manager in the in vivo translational pharmacology unit at Novalix, where she leads a team developing preclinical models, primarily in the field of inflammation, to support compound characterization.